Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Luca Jahreiss"'
Publikováno v:
J Gastrointest Oncol
Background The number and complexity of clinical trials is growing, making finding and accessing trials increasingly challenging. A key barrier to increasing recruitment efficiency is patients' low awareness of trials as an option. They rarely hear a
Publikováno v:
Journal of Clinical Oncology. 39:456-456
456 Background: The number and complexity of clinical trials has been growing, making finding and accessing trials increasingly challenging. Additionally, the goal of representative trial populations remains elusive with sometimes devastating medical
Autor:
Sara Imarisio, Shinji Saiki, Maike Lichtenberg, Fiona M. Menzies, Vojo Deretic, David C. Rubinsztein, Marie Futter, Esteban A. Roberts, Sovan Sarkar, Viktor I. Korolchuk, Cahir J. O'Kane, Farah H. Siddiqi, Luca Jahreiss
Publikováno v:
Nature cell biology
Mammalian target of rapamycin (mTOR) signalling and macroautophagy (henceforth autophagy) regulate numerous pathological and physiological processes including cellular responses to altered nutrient levels. However, the mechanisms regulating mTOR and
Publikováno v:
Nature cell biology
Autophagy is a catabolic process in which lysosomes degrade intracytoplasmic contents transported in double-membraned autophagosomes. Autophagosomes are formed by the elongation and fusion of phagophores, which derive from pre-autophagosomal structur
Publikováno v:
Traffic (Copenhagen, Denmark)
Macroautophagy, a constitutive process in higher eukaryotic cells, mediates degradation of many long-lived proteins and organelles. The actual events occurring during the process in the dynamic system of a living cell have never been thoroughly inves
Publikováno v:
Autophagy. 5(6)
Autophagic cell death has recently received a great deal of attention. However, a dependence of this type of cell death on the actual process of autophagy has only rarely been proven. Indeed, it is important to differentiate between cell death with a
Autor:
David C. Rubinsztein, Fiona M. Menzies, Sovan Sarkar, Ashley R. Winslow, Usha Narayanan, Maike Lichtenberg, Luca Jahreiss, Maria Jimenez-Sanchez, Dunecan Massey, Benjamin R. Underwood, Shouqing Luo, Viktor I. Korolchuk, Brinda Ravikumar, Maurizio Renna, Marie Futter
Autophagy refers to a set of non-specific bulk degradation processes in which cells deliver cytoplasmic substrates for lysosomal degradation. Types of autophagy include macroautophagy, chaperone-mediated autophagy and microautophagy. Chaperone-mediat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0c74c7c3c3921f79814efe4c8c3ac0e
http://hdl.handle.net/11386/2036169
http://hdl.handle.net/11386/2036169
Autor:
Angeleen Fleming, David C. Rubinsztein, Andrea Williams, R.A. Floto, Cahir J. O'Kane, Paul Cuddon, Shinji Saiki, Luca Jahreiss, Dean Pask, Evangelia K. Ttofi, Sovan Sarkar, Paul Goldsmith, Farah H. Siddiqi
Autophagy is a major clearance route for intracellular aggregate-prone proteins causing diseases such as Huntington's disease. Autophagy induction with the mTOR inhibitor rapamycin accelerates clearance of these toxic substrates. As rapamycin has non
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50e43282b638402c45c2b7b586f00e84
https://europepmc.org/articles/PMC2635566/
https://europepmc.org/articles/PMC2635566/
Autor:
Carlo Tacchetti, Consuelo Venturi, Raquel de Pablo, David C. Rubinsztein, Alessandro Fraldi, Carmine Spampanato, Diego L. Medina, Andrea Ballabio, Luca Jahreiss, Carmine Settembre
Publikováno v:
Human molecular genetics. 17(1)
Most lysosomal storage disorders (LSDs) are caused by deficiencies of lysosomal hydrolases. While LSDs were among the first inherited diseases for which the underlying biochemical defects were identified, the mechanisms from enzyme deficiency to cell
Autor:
Shinji Saiki, Luca Jahreiss, David C. Rubinsztein, Fiona M. Menzies, Andrea Williams, Sovan Sarkar, Brinda Ravikumar
Intracellular protein misfolding/aggregation are features of many late-onset neurodegenerative diseases, called proteinopathies. These include Alzheimer's disease, Parkinson's disease, tauopathies, and polyglutamine expansion diseases [e.g., Huntingt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba7142fb6a20dbd7de833139f6186575
https://doi.org/10.1016/s0070-2153(06)76003-3
https://doi.org/10.1016/s0070-2153(06)76003-3